The ABP 654 Study is exploring whether an investigational drug (called ABP 654) works as well as another drug called ustekinumab when used to treat moderate to severe plaque psoriasis.
Our site has two actively enrolling psoriasis trials.
The ABP 654 Study is looking for adults to take part in a research study comparing two medications in patients with moderate-to-severe plaque psoriasis.
You may be eligible to participate if you :
- Are 18-75 years old
- Have had plaque psoriasis for at least 6 months
- Meet additional study criteria.
The CIMcare Study is being conducted find out how a potential treatment behaves in young individuals, ages 6-17 with moderate to severe chronic plaque psoriasis
To make things more convenient for you and your child, some study visits may be performed at home by a qualified nurse!
Your child may qualify for the study if they:
- Are 6-17 years of age
- Have had moderate to severe plaque psoriasis for at least 6 months
- Have a parent, caregiver or legal guardian to help them throughout the study
- Meet additional study criteria
There will be no cost for any study-related investigational product or procedures.
Reimbursement for reasonable, out-of-pocket expenses for travel may be available to qualified individuals.
If you are interested in learning more about this clinical research study, please fill out the form below to see if you may be eligible. By filling out this contact form, you are under no obligation to participate in the study.
You can also reach our staff at (617)851-5354.
For more information, call our office at (617) 851-5354.